piperazine has been researched along with dexrazoxane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
2 other study(ies) available for piperazine and dexrazoxane
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water | 2021 |